)
RetinAI US Inc. (RetinAI), subsidiary of Ikerian AG, is a Swiss & US-based software company improving and supporting R&D of drug candidates, supercharging management and oversight of clinical trials and enabling the research needed to elevate the quality of care on patients with eye diseases.
Focused on the Ophthalmology and Optometry market, RetinAI builds tools to collect, organize and analyze health data from the eyes, enabling healthcare professionals to make the right decisions sooner in healthcare. RetinAI's international team leverages its clinical, technical, and scientific expertise to foster the transition from reactive to preventive medicine for severe eye diseases.
RetinAI’s Discovery® platform is FDA 510k-cleared and CE-Marked under MDR. The company’s AI models for layer, fluid and biomarker segmentation and quantification are CE-Marked under MDR.
Address
Frieburgstasse 3,Bern
3010
Switzerland